This HTML5 document contains 24 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n5http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n4http://linked.opendata.cz/ontology/mesh/
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C29061
rdf:type
owl:Class
rdfs:label
Fluticasone Propionate
rdfs:subClassOf
nci:C521
nci:A8
nci:C63923
nci:P106
Steroid Pharmacologic Substance
nci:P108
Fluticasone Propionate
nci:P207
C0117996
nci:P210
80474-14-2
nci:P319
O2GMZ0LF5W
nci:P322
FDA
nci:P350
C25H31F3O5S
nci:P366
Fluticasone_Propionate
nci:P368
CHEBI:31441
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>FLUTICASONE PROPIONATE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>O2GMZ0LF5W</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Fluticasone Propionate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>(6alpha,11beta,16alpha,17alpha)-6,9-Difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic Acid, S-(Fluoromethyl) Ester</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Fluticasone Propionate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>50239</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Flonase</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Flovent</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C29061
owl:sameAs
n7:O2GMZ0LF5W
n4:hasConcept
n5:M0179831